Mounjaro vs Ozempic: How They Compare (2026)

By Nouri Editorial Team · Medically reviewed by Amber Patel, MD · Last updated June 28, 2026

See if you qualify in 5 minutes →
5-minute questionnaire · reviewed by a licensed clinician · The Nouri Promise: 30-day full refund on 3- and 6-month plans · cancel anytime

At a glance: Mounjaro vs Ozempic

*As of June 2026 per publicly available manufacturer list pricing; insurance, copay assistance cards, and manufacturer savings programs significantly affect out-of-pocket cost. Verify against current pricing before prescribing or purchasing. Efficacy figures cited in this article are from trials of the FDA-approved branded medications and are population averages, not individual guarantees.

Two different mechanisms: dual vs single receptor

Ozempic (semaglutide) mimics GLP-1 (glucagon-like peptide-1), a hormone released by the gut after eating. GLP-1 signals the pancreas to secrete insulin in response to meals, slows gastric emptying so food stays in the stomach longer, and reduces appetite signals in the brain. Novo Nordisk first received FDA approval for weekly subcutaneous semaglutide (Ozempic) for type 2 diabetes in December 2017.

Mounjaro (tirzepatide) activates two hormonal receptors simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is the other principal incretin hormone, secreted by cells in the small intestine in response to meals. The dual mechanism appears to amplify insulin secretion, enhance appetite suppression, and — based on clinical trials — produce larger reductions in both blood sugar and body weight than single-receptor GLP-1 therapies. Eli Lilly received FDA approval for Mounjaro (tirzepatide for type 2 diabetes) in May 2022.

The practical implication: tirzepatide has a broader metabolic reach within its trials, but both drugs lower A1C and reduce weight meaningfully compared to placebo. The right choice depends on a patient's full clinical picture, not just which molecule performed better on average in a population study.

How do the dosing schedules compare?

Both Mounjaro and Ozempic are administered once weekly by subcutaneous injection (just under the skin) using a pre-filled auto-injection pen, on the same day each week. Injection sites — abdomen, thigh, or upper arm — are rotated to minimize local reactions.

Ozempic dose ladder: begins at 0.25 mg/week for four weeks (for tolerability), then escalates to 0.5 mg/week as the typical maintenance dose. The clinician may increase to 1.0 mg/week if additional glycemic control is needed, and the 2.0 mg dose is available for patients who require further A1C reduction. The pen is color-coded to each dose strength.

Mounjaro dose ladder: begins at 2.5 mg/week for four weeks, then increases by 2.5 mg every four weeks as tolerated. Maintenance doses range from 5 mg through 15 mg/week — a longer titration staircase that reflects the broader dose range available. Patients who find 5 mg or 7.5 mg effective and well-tolerated may not need to escalate further.

The wider dose range of Mounjaro means the titration period can last several months before a patient reaches their stable maintenance dose. For both drugs, dose escalations are made by the prescribing clinician based on blood-sugar response and tolerability.

What do the clinical trials show about weight loss?

Semaglutide trial data (Ozempic's molecule)

The landmark STEP-1 trial (Wilding et al., NEJM 2021) tested weekly semaglutide 2.4 mg (the weight-management dose, marketed as Wegovy) in adults with obesity or overweight and no diabetes. Participants lost a mean of approximately 14.9% of body weight over 68 weeks, versus 2.4% with placebo. At Ozempic's approved diabetes doses (0.5–2.0 mg), weight reductions are clinically meaningful but typically lower than at the 2.4 mg weight-management dose.

The SELECT trial (Lincoff et al., NEJM 2023) tested semaglutide 2.4 mg in adults with obesity and established cardiovascular disease but without diabetes, finding a 20% relative risk reduction in major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) versus placebo. This cardiovascular outcome data informed Wegovy's expanded label; Ozempic's own cardiovascular indication in type 2 diabetes patients is based on the separate SUSTAIN-6 trial, per the Ozempic FDA label.

Tirzepatide trial data (Mounjaro's molecule)

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) tested weekly tirzepatide at weight-management doses in adults with obesity or overweight and no diabetes. Participants on tirzepatide 15 mg lost a mean of approximately 20.9% of body weight over 72 weeks, versus 3.1% with placebo — a result that drew significant attention for its magnitude.

Head-to-head: tirzepatide vs semaglutide

The SURMOUNT-5 trial (NEJM 2025) is the highest-quality direct comparison available as of mid-2026. It compared tirzepatide to semaglutide 2.4 mg (Wegovy) in adults with obesity. Tirzepatide participants lost a mean of approximately 20.2% of body weight; semaglutide participants lost approximately 13.7% — tirzepatide producing roughly 47% more relative weight loss in this trial population.

These are population-level averages from well-controlled trials of the branded drugs. A meaningful proportion of patients in every trial arm lose significantly more or less than the mean; the right therapy and dose for any individual requires a full clinical review by a licensed provider. See the NIDDK overview of prescription medications for obesity for an evidence-based summary of the full GLP-1 class.

For a detailed molecule-level comparison, see our guide to tirzepatide vs semaglutide. For the head-to-head weight-loss analysis of their weight-management versions, see which GLP-1 is most effective for weight loss.

How do side effects compare?

The side-effect profiles of Mounjaro and Ozempic are broadly similar in type, reflecting their shared GLP-1 activity. The most commonly reported adverse events are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These occur most often early in treatment and during dose escalation, and they typically improve as the body adjusts. Slowing the titration schedule can help manage them.

Both drugs carry an FDA boxed warning for thyroid C-cell tumors, based on rodent studies (clinical significance in humans is not established). Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Both also carry risk disclosures for pancreatitis and gallbladder disease, including gallstones.

Because tirzepatide's dual mechanism and potentially higher maintenance doses may involve a longer titration, some prescribers counsel patients that GI side effects may require more careful management during dose escalation — though trial populations differ and direct comparisons are difficult. Both drugs are contraindicated in pregnancy.

Neither drug should be started, stopped, or dose-adjusted without guidance from the prescribing clinician. For a broader comparison of GI and other tolerability data across the class, see our guide to which GLP-1 has the fewest side effects.

What are each drug's FDA-approved indications?

Mounjaro (tirzepatide) is FDA-approved to improve glycemic control in adults with type 2 diabetes, as an adjunct to diet and exercise. It is not FDA-approved for weight loss — that is Zepbound (same molecule, weight-management label and dose range). See the Mounjaro FDA prescribing information for full indication and contraindication detail.

Ozempic (semaglutide) is FDA-approved for type 2 diabetes and — following cardiovascular outcomes data from the SUSTAIN-6 trial — also to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease. It is not FDA-approved for weight loss — that is Wegovy (semaglutide 2.4 mg). See the Ozempic FDA prescribing information for full indication and contraindication detail.

Clinicians sometimes prescribe Mounjaro or Ozempic off-label for weight management, but patients specifically seeking FDA-approved weight-loss treatment should discuss Zepbound or Wegovy with their provider. For a direct comparison of the weight-loss versions, see Ozempic vs Wegovy.

How much do Mounjaro and Ozempic cost without insurance?

Both branded GLP-1 medications carry manufacturer list prices of approximately $1,000–$1,100/month as of June 2026, per publicly available Eli Lilly and Novo Nordisk list pricing. Very few patients pay the full list price:

• Commercial insurance often covers both drugs for type 2 diabetes (prior authorization is common), reducing out-of-pocket cost substantially, though coverage and copay tiers vary widely by plan.
• Manufacturer savings cards (for eligible commercially insured patients) can reduce monthly cost to as low as $25–$99 for qualifying patients. Check LillyDirect.com and NovoNordisk.com for current programs.
• Medicare Part D typically covers Ozempic and Mounjaro for type 2 diabetes, not for weight loss, with variable cost-sharing.
• Cash-pay programs (e.g., Lilly Insulin Value Program, NovoCare) offer reduced prices for uninsured patients at specific dose levels.

Prices and program eligibility change frequently. For a full up-to-date comparison of GLP-1 costs across brand and compounded options, including 2026 pricing data, see our GLP-1 cost guide for 2026 and the Nouri GLP-1 telehealth pricing dataset.

Where does compounded tirzepatide or semaglutide fit?

When brand-name GLP-1 medications are inaccessible — due to cost, prior authorization delays, or persistent shortages — some patients obtain compounded semaglutide or compounded tirzepatide through state-licensed 503A compounding pharmacies, prescribed by a U.S.-licensed clinician when clinically appropriate. See the FDA's overview of human drug compounding and the FDA's GLP-1 compounding safety guidance for the regulatory context.

Important disclosure: Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not the same as — or therapeutically equivalent to — Ozempic, Wegovy, Mounjaro, or Zepbound. They are patient-specific preparations, prescribed only when a U.S.-licensed clinician determines it is clinically appropriate. Not all applicants qualify. For a detailed cost comparison of brand vs compounded options, see compounded vs brand GLP-1 cost.

If you and a licensed clinician determine a GLP-1 is right for you, Nouri offers compounded semaglutide and compounded tirzepatide as part of The Program — one all-inclusive membership that combines the medication (when prescribed), a personalized nutrition plan, a movement plan, and concierge care at one price:

• Compounded semaglutide: $120/month on the 6-month plan ($720 every 6 months) · $145/month on the 3-month plan ($435 every 3 months) · $175/month billed monthly.
• Compounded tirzepatide: $175/month on the 6-month plan ($1,050 every 6 months) · $199/month on the 3-month plan ($597 every 3 months) · $225/month billed monthly.
• Any dose, same price. Available in all 50 U.S. states.

Medication is prepared by state-licensed 503A compounding pharmacies — Jungle Jim's Pharmacy (Fairfield, OH) and VialsRX — and ships free and discreetly. Nouri is LegitScript-certified. The Nouri Promise: if you're not satisfied in your first 30 days, you get a full refund — available on 3-month and 6-month plans.

Start your 5-minute assessment →
5-minute questionnaire · reviewed by a licensed clinician · 30-day full refund on 3- and 6-month plans · cancel anytime

Related comparisons in this series

• Tirzepatide vs Semaglutide — the molecule-level comparison
• Ozempic vs Wegovy — same molecule, different indications
• Zepbound vs Ozempic — the weight-loss version of this comparison
• Which GLP-1 is most effective for weight loss?
• Which GLP-1 has the fewest side effects?
• GLP-1 cost guide 2026 — full pricing breakdown

Frequently asked questions

Is Mounjaro the same as Ozempic?

No. Both are FDA-approved weekly injections for type 2 diabetes, but they are entirely different drugs. Mounjaro is tirzepatide — a dual GIP/GLP-1 receptor agonist from Eli Lilly (max 15 mg/week). Ozempic is semaglutide — a GLP-1 receptor agonist from Novo Nordisk (max 2.0 mg/week). They have different molecular structures, different mechanisms of action, and different dosing scales.

Which causes more weight loss, Mounjaro or Ozempic?

In clinical trials of the branded medications, tirzepatide (the molecule in Mounjaro and Zepbound) has generally produced greater weight loss than semaglutide (the molecule in Ozempic and Wegovy). In the head-to-head SURMOUNT-5 trial comparing tirzepatide to semaglutide 2.4 mg, mean body-weight loss was ~20.2% versus ~13.7%, respectively. These are population averages from studies of the FDA-approved branded drugs — individual results vary substantially, and a licensed clinician determines what is appropriate for you.

Are Mounjaro and Zepbound the same drug?

Yes — both are tirzepatide made by Eli Lilly. Mounjaro is the diabetes label (approved for glycemic control in type 2 diabetes); Zepbound is the weight-management label (approved for chronic weight management in adults with obesity or overweight with a qualifying condition). Same active ingredient, different FDA-approved indications and dosing presentations.

Is Mounjaro stronger than Ozempic?

In clinical trials, tirzepatide (Mounjaro) has produced larger A1C and body-weight reductions than semaglutide (Ozempic) on average, which researchers attribute to its dual GIP/GLP-1 receptor activity and the additional metabolic effects of GIP agonism. Whether tirzepatide is the appropriate choice for a given patient depends on their full medical history, comorbidities, tolerability, and treatment goals — a licensed clinician makes that determination, not a drug comparison article.

What is the difference between Mounjaro and Wegovy?

They are different molecules with different approved uses. Mounjaro is tirzepatide (FDA-approved for type 2 diabetes). Wegovy is semaglutide 2.4 mg (FDA-approved for chronic weight management). Mounjaro's weight-loss equivalent is Zepbound; Wegovy's diabetes-label equivalent is Ozempic. For weight-loss comparisons of the weight-management products, see which GLP-1 is most effective for weight loss.

Can I get tirzepatide or semaglutide without the brand-name product?

Some patients obtain compounded semaglutide or compounded tirzepatide through state-licensed 503A compounding pharmacies, prescribed by a U.S.-licensed clinician when clinically appropriate. Compounded forms are not FDA-approved and are not the same as or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound. They are patient-specific preparations; not all applicants qualify. If you are interested in whether a compounded option may be appropriate for you, completing a medical intake with a licensed provider is the first step.

Sources & references

1. STEP-1: Once-Weekly Semaglutide in Adults with Overweight or Obesity — Wilding JPH et al., NEJM 2021 (Tier 1)
2. SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity — Jastreboff AM et al., NEJM 2022 (Tier 1)
3. SURMOUNT-5: Tirzepatide vs Semaglutide for Obesity (head-to-head) — NEJM 2025 (Tier 1)
4. SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes — Lincoff AM et al., NEJM 2023 (Tier 1)
5. Mounjaro (tirzepatide) FDA prescribing information — Eli Lilly, 2025 (Tier 1)
6. Ozempic (semaglutide) FDA prescribing information — Novo Nordisk, 2025 (Tier 1)
7. NIDDK: Prescription Medications to Treat Overweight & Obesity — NIH, National Institute of Diabetes and Digestive and Kidney Diseases (Tier 1)
8. FDA: Human Drug Compounding (Tier 1)
9. FDA: Postmarket Drug Safety Information — GLP-1 Compounding Concerns (Tier 1)
10. Nouri GLP-1 Telehealth Pricing Dataset 2026 — HuggingFace (nouriadmin)

Medically reviewed by Amber Patel, MD · Review date: June 28, 2026. Nouri content is reviewed by a licensed clinician and updated as guidance changes. Author: Nouri Editorial Team.

This article is for general education only and does not constitute medical advice — consult a licensed clinician about what is right for you. Ozempic®, Wegovy®, and Rybelsus® (semaglutide) are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® (tirzepatide) are registered trademarks of Eli Lilly and Company. Nouri is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. Clinical trial results cited in this article are from studies of the FDA-approved branded medications in their respective trial populations; compounded semaglutide and compounded tirzepatide have not been studied in these trials, are not FDA-approved, and are not the same as — or therapeutically equivalent to — the brand-name drugs named above. GLP-1 medications carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies (clinical relevance in humans is not established); they are contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Other risks include pancreatitis and gallbladder disease. These medications are not for use in pregnancy. Brand-name and compounded drug prices change frequently; verify against current pricing before making any financial or clinical decision. Individual results vary.